Strontium ranelate - New paradigm in the treatment of postmenopausal osteoporosis;Stroncij ranelat - Nova paradigma za liječenje postmenopauzalne osteoporoze

Lijecnicki Vjesnik

Volumn 128, Issue 5-6, 2006, Pages 180-182

  Koršić, Mirko ^a   Giljević, Zlatko ^a   Kaštelan, Darko ^a,b  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b KBC Zagreb   (Croatia)

Author keywords

Fractures, bone prevention and control, etiology; Organometallic compounds therapeutic use, administration and dosage; Osteoporosis, postmenopausal drug therapy, complications; Thiophenes therapeutic use, administration and dosage

Indexed keywords

PARATHYROID HORMONE[1-34]; STRONTIUM RANELATE;

CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG USE; HUMAN; POSTMENOPAUSE OSTEOPOROSIS; PRESCRIPTION; SHORT SURVEY;

BONE DENSITY CONSERVATION AGENTS; FEMALE; HUMANS; ORGANOMETALLIC COMPOUNDS; OSTEOPOROSIS, POSTMENOPAUSAL; THIOPHENES;

EID: 33746745357     PISSN: 00243477     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (17)

1. Gabriel SE, Tosteson AN, Leibson CL i sur. Direct medical costs attributable to osteoporotic fractures. Osteoporosis Int 2002;13:323-30.
2. Strewler GJ. Decimal Point - Osteoporosis Therapy at the 10-Year Mark. N Engl J Med 2004;350:1172-1174.
3. Giljević Z. Značaj problema osteoporoze_u Hrvatskoj. U: 3. hrvatski kongres o osteoporozi, Zbornik sažetaka. Šibenik, 2005, str. 19.
4. Liberman UA, Weiss SR, Broll J i sur. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995;333:1437-43.
5. Harris ST, Watts NB, Genant HK i sur. Effect of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal Osteoporosis: a randomized controlled trial. JAMA 1999;282:1344-52.
6. Chesnut CH III, Skag A, Christiansn C i sur. Effects of oral ibandronate administred daily or intermittently on fracture risk in postmenopausal Osteoporosis. J Bone Miner Res 2004;19:1241-9.
7. Ettinger B., Black DM, Mitlak BH i sur. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999;282:637-45.
8. Chesnut C, Majumdar S, Gardner J i sur. Assessment of bone quality-quantity and turnover with multiple methodologies at multiple skeletal sites. Adv Exp Med Biol 2001;496:95-7.
9. Neer RM, Arnaud CK, Zanchetta JR i sur. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with Osteoporosis. N Engl J Med 2001;344:1434-41.
10. Meunier PJ, Roux C, Seeman E i sur. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350:459-468.
11. Boivin G, Deloffree P, Perrat B i sur. Strontium distribution and interactions with bone mineral in monkey iliac bone after strontium salt (S 12911) administration. J Bone Miner Res 1997;11:1302-1311.
12. Marie PJ, Amman P, Boivin G, Key C. Mechanisms of action and therapeutic potential of strontium in bone. Calcif Tissue Int 2001;69:121-129.
13. Delannoy P, Bazot D, Marie PJ. Long-term treatment with strontium ranelate increases vertebral bone mass without deleterious effect in mice. Metabolism 2002;51:906-911.
14. Marie PJ, Hott M, Modrowski D i sur. An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats. J Bone Miner Res 1993;9:607-615.
15. Boivin G, Meunier PJ. The mineralization of bone tissue: a forgotten dimension in Osteoporosis research. Osteoporosis Int 2003;14(Suppl 3):S19-S24.
16. Reginster JY, Seeman MC, De Vernejoul S i sur. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with Osteoporosis: Treatment of peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005;90:2816-2822.
17. Quarles LD. Cation sensing receptors in bone: A novel paradigm for regulation bone remodeling? J Bone Miner Res 1997;12:1971-1974.